FLT3 and acute myeloid leukemia: Given the increasing use of low-intensity regimens in AML, pooled data from VIALE-A [48] and a phase 1b HMA/VEN study [70] showed that patients with FLT3-ITD had a CR/CRi rate of 63% with AZA/VEN and a median OS of 9.9 months, while those with FLT3-TKD had a CR/CRi rate of 77% and a median OS of 19.2 months [127].